Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of oral FHD-286 in metastatic uveal melanoma
NL-OMON53846Phase 1Active, not recruiting
- Sponsor
- Foghorn Therapeutics
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of camibirstat in intraocular melanoma (2 arms), sponsored by Foghorn Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events and Safety laboratory assessments. Started Mar 2023; status: active, not recruiting.
02
Drugs
camibirstat
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON53846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53846.